Drug-Eluting Stent Thrombosis in Routine Clinical Practice: Two-Year Outcomes and Predictors From the TAXUS ARRIVE Registries

John M. Lasala(Lehigh Valley Hospital-Pocono), David A. Cox(Eli Lilly (United States)), D. S. Baim(United Heart and Vascular Clinic), Aijun Song(Lehigh Valley Hospital-Pocono), William Bachinsky, D. Dobies(United Heart and Vascular Clinic), E. W. Rogers(St Vincent Hospital), J. A. Breall(United Heart and Vascular Clinic), D. H. Lewis(United Heart and Vascular Clinic), Kayla Garzio Baran(United Heart and Vascular Clinic), Stephen R. Mascioli(Lehigh Valley Hospital-Pocono), Ruth M. Starzyk(Boston Scientific (United States)), K Dawkins(Southampton Hospital)
Circulation Cardiovascular Interventions
August 1, 2009
10.1161/circinterventions.109.852178
Cited by 20

Related Papers

Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial
|The Lancet|2020|586
Relationship Between Osteoporosis and Cardiovascular Disease in Postmenopausal Women
|Journal of Bone and Mineral Research|2005|538
Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier.
|Proceedings of the National Academy of Sciences|1991|409
A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial
|The Lancet|2018|288
Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease
|Circulation|2017|214